PHILADELPHIA, PA — Proscia this week launched a major update to its Concentriq digital pathology platform, embedding new artificial intelligence capabilities aimed at helping diagnostic laboratories and pharmaceutical companies manage rising workloads, accelerate biomarker research and expand precision medicine programs.
The Philadelphia-based company introduced the fifth generation of Concentriq this week, marking its largest platform overhaul in five years. The release arrives as pathology departments face staffing pressures and life sciences companies seek faster ways to identify biomarkers and advance targeted therapies.
Proscia reports that its software is used by laboratories handling approximately 12 million patient cases annually and by 16 of the world’s 20 largest pharmaceutical companies.
The new platform architecture integrates vision, language and multimodal AI models designed specifically for pathology workflows. According to the company, the system combines medical images, patient information, laboratory data and research datasets to support clinical decision-making and scientific analysis.
Chief Technology Officer Coleman Stavish described the redesign as an effort to reduce administrative and analytical burdens surrounding case review.
“Years of learning from our customers have helped us understand where complexity slows them down and where judgment gets crowded out by process,” Stavish noted. “Fifth Generation is designed to reduce that burden so experts can focus on the decisions that matter most.”
For diagnostic laboratories, the software is intended to streamline case review, automate operational tasks and support expansion into molecular testing and precision medicine services.
The platform includes AI-assisted image navigation, integrated image analysis tools, workload management features and automated data-storage capabilities. Proscia estimates the storage architecture can reduce long-term storage costs by more than half while maintaining access to historical case data.
The company also positions the platform as a growth tool for laboratories pursuing collaborations with pharmaceutical companies in areas such as clinical trials, companion diagnostics and real-world evidence programs.
For drug developers, Concentriq is designed to support biomarker discovery, clinical trial enrollment and diagnostic development. Scientists can search tissue, clinical and translational datasets using natural-language queries, while AI tools identify relevant evidence and propose analytical workflows.
The platform also includes capabilities intended to support biomarker-driven clinical trials by helping sponsors identify eligible patients and maintain consistent evaluation criteria across multiple research sites.
Dr. Derek Welch, president and chief medical officer of PathGroup, characterized the new system as an effort to reduce administrative work surrounding pathology review.
“Fifth Generation applies AI in an entirely new way, removing the invisible labor that surrounds case review so pathologists can spend more time on the decisions that only they can make,” Welch stated.
Dr. John Cochran, vice president and chief medical officer of IQVIA Laboratories, highlighted the platform’s role in supporting pathology testing for drug development programs across multiple international laboratories.
Initial deployments of the upgraded platform are scheduled to begin this month through Proscia’s early-access program, with broader availability planned later this year.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.